MVC obtained TPEX's (Taipei Exchange) approval for listing on Taiwan OTC Exchange (TWO) on December 22nd.
MVC focuses on developing novel vaccines including EV71 vaccine, H7N9 mock-up vaccine, and Dengue vaccine and applied for TWO approval as technology-based enterprise with paid-in capital as 1,367.65 million TWD.
MVC received recommendations from three security firms including Sinopac Securities Corporation, Fubon Financial Holding Corporation, and TCStock Corporation.
Please visit TPEX website for more information: